Cyclerion Therapeutics, Inc. (CYCN)
- Previous Close
2.8300 - Open
2.7400 - Bid --
- Ask --
- Day's Range
2.7400 - 2.9000 - 52 Week Range
1.7500 - 5.2500 - Volume
6,236 - Avg. Volume
5,307 - Market Cap (intraday)
6.919M - Beta (5Y Monthly) 1.91
- PE Ratio (TTM)
-- - EPS (TTM)
-4.2900 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
www.cyclerion.comRecent News: CYCN
View MorePerformance Overview: CYCN
Trailing total returns as of 9/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCN
View MoreValuation Measures
Market Cap
6.92M
Enterprise Value
2.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.79
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.55%
Return on Equity (ttm)
-150.25%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.47M
Diluted EPS (ttm)
-4.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.39M